Profile data is unavailable for this security.
About the company
Cabaletta Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on the discovery and development of engineered T cell therapies that have the potential to provide deep and durable, perhaps curative, responses with one-time administration for patients with autoimmune diseases. Its Cabaletta Approach to B cell Ablation (CABA) platform encompasses two strategies: Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) and Chimeric AutoAntibody Receptor T cells (CAART). CABA-201, its lead product candidate from its CARTA platform, is a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T construct designed to treat patients with a range of autoimmune diseases. Its DSG3-CAART product candidate is being evaluated for the treatment of mPV, a subtype of PV that affects the epithelium of the mucous membranes, in the Phase 1 DesCAARTes TM trial. Its MuSK-CAART product candidate is designed to treat a subset of patients with MG, targeting autoreactive B cells.
- Revenue in USD (TTM)0.00
- Net income in USD-76.87m
- Incorporated2017
- Employees118.00
- LocationCabaletta Bio Inc2929 Arch Street, Suite 600PHILADELPHIA 19104United StatesUSA
- Phone+1 (267) 759-3100
- Fax+1 (302) 655-5049
- Websitehttps://www.cabalettabio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eyepoint Pharmaceuticals Inc | 50.02m | -78.92m | 488.55m | 121.00 | -- | 1.87 | -- | 9.77 | -1.83 | -1.83 | 1.17 | 5.01 | 0.2068 | 1.14 | 7.44 | 413,380.20 | -32.62 | -40.44 | -40.06 | -47.79 | 90.50 | 83.45 | -157.77 | -186.23 | 5.01 | -- | 0.00 | -- | 11.14 | -- | 30.77 | -- | -- | -- |
| Allogene Therapeutics Inc | 87.00k | -292.30m | 489.70m | 232.00 | -- | 0.8682 | -- | 5,628.76 | -1.78 | -1.78 | 0.0005 | 2.71 | 0.0001 | -- | -- | 375.00 | -43.85 | -28.46 | -47.04 | -30.21 | -- | -- | -335,973.60 | -1,123.44 | -- | -- | 0.00 | -- | -39.10 | -- | 3.86 | -- | -14.06 | -- |
| OmniAB Inc | 21.05m | -63.48m | 496.34m | 106.00 | -- | 1.64 | -- | 23.58 | -0.634 | -0.634 | 0.2103 | 2.57 | 0.055 | -- | 7.18 | 198,547.20 | -16.58 | -- | -17.48 | -- | -- | -- | -301.63 | -- | -- | -- | 0.00 | -- | -42.17 | -- | -126.65 | -- | -- | -- |
| Astria Therapeutics Inc | 0.00 | -81.63m | 502.45m | 59.00 | -- | 1.84 | -- | -- | -2.32 | -2.32 | 0.00 | 6.70 | 0.00 | -- | -- | 0.00 | -27.34 | -64.48 | -28.18 | -68.34 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -40.62 | -- | -- | -- |
| ORIC Pharmaceuticals Inc | 0.00 | -101.76m | 504.99m | 102.00 | -- | 1.54 | -- | -- | -1.81 | -1.81 | 0.00 | 4.87 | 0.00 | -- | -- | 0.00 | -35.25 | -33.92 | -37.18 | -35.77 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -12.99 | -- | 10.09 | -- |
| SNDL Inc | 658.39m | -99.36m | 507.96m | 2.52k | -- | 0.5771 | -- | 0.7715 | -0.3795 | -0.3883 | 2.52 | 3.38 | 0.5855 | 4.67 | 33.35 | 261,682.80 | -9.19 | -24.44 | -9.95 | -27.94 | 24.97 | 22.49 | -15.69 | -62.17 | 2.86 | -83.91 | 0.1157 | -- | 27.63 | -- | 49.83 | -- | -- | -- |
| Kalvista Pharmaceuticals Inc | 0.00 | -108.30m | 509.21m | 118.00 | -- | 4.71 | -- | -- | -3.14 | -3.14 | 0.00 | 2.56 | 0.00 | -- | -- | 0.00 | -68.23 | -33.56 | -75.55 | -36.55 | -- | -- | -- | -941.88 | -- | -- | 0.00 | -- | -- | -- | -12.83 | -- | -3.47 | -- |
| Replimune Group Inc | 0.00 | -215.79m | 513.74m | 331.00 | -- | 1.37 | -- | -- | -3.24 | -3.24 | 0.00 | 6.10 | 0.00 | -- | -- | 0.00 | -38.05 | -29.08 | -40.71 | -30.56 | -- | -- | -- | -- | -- | -- | 0.1593 | -- | -- | -- | -23.82 | -- | 16.84 | -- |
| Cabaletta Bio Inc | 0.00 | -76.87m | 514.63m | 118.00 | -- | 2.32 | -- | -- | -1.73 | -1.73 | 0.00 | 4.60 | 0.00 | -- | -- | 0.00 | -44.70 | -33.76 | -48.55 | -35.68 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.75 | -- | -- | -- |
| Erasca Inc | 0.00 | -126.86m | 516.42m | 126.00 | -- | 1.14 | -- | -- | -0.8423 | -0.8423 | 0.00 | 1.91 | 0.00 | -- | -- | 0.00 | -30.29 | -- | -32.45 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 48.50 | -- | -- | -- |
| Y-mAbs Therapeutics Inc | 84.50m | -21.67m | 522.64m | 100.00 | -- | 5.27 | -- | 6.19 | -0.496 | -0.496 | 1.93 | 2.26 | 0.6481 | 1.31 | 4.30 | 844,990.00 | -16.62 | -44.23 | -19.95 | -50.45 | 86.53 | -- | -25.64 | -181.13 | 5.67 | -- | 0.00 | -- | 29.96 | -- | 77.58 | -- | -- | -- |
| Northwest Biotherapeutics Inc | 1.34m | -72.21m | 523.10m | 25.00 | -- | -- | -- | 391.54 | -0.0629 | -0.0629 | 0.0012 | -0.0447 | 0.0435 | -- | -- | 53,440.00 | -228.72 | -381.58 | -- | -- | -- | -- | -5,258.91 | -6,479.25 | -- | -10.49 | -- | -- | 14.80 | 36.21 | 38.71 | -- | 77.88 | -- |
| Celcuity Inc | 0.00 | -73.45m | 527.57m | 55.00 | -- | 3.46 | -- | -- | -2.79 | -2.79 | 0.00 | 4.35 | 0.00 | -- | -- | 0.00 | -41.61 | -37.32 | -44.44 | -39.16 | -- | -- | -- | -- | -- | -- | 0.2193 | -- | -- | -- | -57.99 | -- | -31.12 | -- |
| Terns Pharmaceuticals Inc | 0.00 | -91.06m | 530.35m | 66.00 | -- | 2.24 | -- | -- | -1.26 | -1.26 | 0.00 | 3.66 | 0.00 | -- | -- | 0.00 | -33.23 | -41.34 | -34.55 | -45.70 | -- | -- | -- | -31,010.30 | -- | -- | 0.00 | -- | -- | -- | -49.49 | -- | -26.60 | -- |
| Entrada Therapeutics Inc | 162.87m | 23.49m | 532.72m | 160.00 | 25.16 | 1.97 | 19.89 | 3.27 | 0.6273 | 0.6273 | 4.79 | 8.02 | 0.3302 | -- | 3.89 | 1,024,359.00 | 4.76 | -- | 7.06 | -- | -- | -- | 14.42 | -- | -- | -- | 0.00 | -- | -- | -- | 92.93 | -- | -- | -- |
| Corbus Pharmaceuticals Holdings Inc | 0.00 | -33.76m | 535.40m | 19.00 | -- | 5.43 | -- | -- | -6.97 | -6.97 | 0.00 | 9.23 | 0.00 | -- | -- | 0.00 | -38.06 | -86.84 | -49.24 | -130.46 | -- | -- | -- | -769.76 | -- | -15.43 | 0.1179 | -- | -- | -- | -5.33 | -- | -- | -- |
Data as of Jun 14 2024. Currency figures normalised to Cabaletta Bio Inc's reporting currency: US Dollar USD
57.01%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Jennison Associates LLCas of 31 May 2024 | 5.17m | 10.71% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 3.74m | 7.75% |
| Fred Alger Management LLCas of 31 Mar 2024 | 3.11m | 6.44% |
| Adage Capital Management LPas of 31 Mar 2024 | 3.04m | 6.29% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 2.76m | 5.71% |
| T. Rowe Price Investment Management, Inc.as of 31 Mar 2024 | 2.47m | 5.12% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 2.19m | 4.53% |
| Lynx1 Capital Management LPas of 31 Mar 2024 | 2.08m | 4.32% |
| Perceptive Advisors LLCas of 31 Mar 2024 | 1.72m | 3.56% |
| Polar Capital LLPas of 31 Mar 2024 | 1.25m | 2.59% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
